
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics Inc demonstrates a strong potential for stock growth, primarily due to the promising advancements in its lead candidate, FHD-286, which exhibits significant mutational activity in acute myeloid leukemia (AML) and has shown favorable efficacy markers in heavily pretreated patient populations. Additionally, the company’s progress in its EP300 and CBP programs, with ongoing IND studies and preclinical data supporting their safety and effectiveness, positions Foghorn therapeutics to capitalize on innovative treatment strategies in oncology. Furthermore, the successful IND clearance for FHD-909 and the planned Phase 1 study initiation highlight an expanding pipeline, which enhances the company's ability to meet diverse cancer treatment needs and increase its market viability.
Bears say
Foghorn Therapeutics Inc reported a net loss of $22.9 million for the second quarter of 2024, a reduction from the $29.4 million loss recorded in the same quarter of the previous year, highlighting ongoing financial challenges despite slightly improved performance. The development of key drug candidates, FHD-286 and FHD-609, remains fraught with uncertainties, particularly surrounding the potential inefficacy of FHD-286 and possible safety concerns that could halt its progression. Additionally, considerable risks persist related to clinical and regulatory setbacks, as well as the company's ability to meet future sales projections, which contribute to a generally negative outlook for Foghorn's stock performance.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares